Assuntos
COVID-19 , Pandemias , Fototerapia , COVID-19/epidemiologia , COVID-19/prevenção & controle , Desinfecção/métodos , Contaminação de Equipamentos , Higiene das Mãos , Humanos , Doenças Profissionais/prevenção & controle , Equipamento de Proteção Individual , Fototerapia/instrumentação , SARS-CoV-2/efeitos da radiação , Espanha/epidemiologia , Raios UltravioletaRESUMO
INTRODUCTION: Solar urticaria is an uncommon photodermatosis. First-line treatment is with antihistamines; second-line treatment includes induction of light tolerance using UV phototherapy. OBJECTIVES: We aimed to describe and evaluate the effectiveness of a desensitization protocol with narrowband UV-B in patients with solar urticaria. MATERIAL AND METHODS: We performed a retrospective study of patients with solar urticaria with an action spectrum in the UV-A range, the visible light range, or both who had received therapy with narrowband UV-B for induction of light tolerance. Short courses of treatment were administered (<20 sessions, 3 per week) during spring. The initial dose was determined according to the skin type. The Skindex-29 was administered before treatment and after summer; a nonvalidated questionnaire was also administered after summer to evaluate disease activity and satisfaction with treatment. RESULTS: We included 8 patients with an action spectrum (4 with visible light and 4 with UVA plus visible light). Seventeen courses (1-6 per patient) were administered per year. The number of sessions per year ranged from 11 to 20. The mean dose of narrowband UV-B per course was 7.45J/cm2. No patients experienced flares or adverse effects during treatment. The response was satisfactory in 6 patients. The improvement in the overall Skindex-29 score was greater than 20% in 78.6% of cases. The improvement in the function and symptoms subscales was over 20% in 71% and 64% of cases, respectively. CONCLUSION: Induction of light tolerance with narrowband UV-B in solar urticaria is safe and effective in a high percentage of patients.
Assuntos
Transtornos de Fotossensibilidade/radioterapia , Luz Solar/efeitos adversos , Terapia Ultravioleta , Urticária/radioterapia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Estudos Retrospectivos , Terapia Ultravioleta/métodos , Adulto JovemRESUMO
We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy.
Assuntos
Omalizumab/uso terapêutico , Transtornos de Fotossensibilidade/tratamento farmacológico , Urticária/tratamento farmacológico , Idoso , Avaliação de Medicamentos , Resistência a Medicamentos , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Humanos , Iluminação/efeitos adversos , Masculino , Pessoa de Meia-Idade , Omalizumab/efeitos adversos , Transtornos de Fotossensibilidade/etiologia , Transtornos de Fotossensibilidade/psicologia , Fototerapia , Qualidade de Vida , Luz Solar/efeitos adversos , Urticária/etiologia , Urticária/psicologiaRESUMO
BACKGROUND: Solar urticaria is a chronic inducible urticaria also classified as an idiopathic dermatosis. The objective of this paper is to define the phenotypic characteristics of solar urticaria and to evaluate its incidence. MATERIAL AND METHOD: This was a retrospective multicenter study in which data were gathered on the epidemiology and clinical, photobiologic, laboratory, and therapeutic characteristics of solar urticaria. RESULTS: A total of 224 patients (141 women and 83 men) were included from 9 photobiology units. The mean age of the patients was 37.9 years (range, 3-73 years). A history of atopy was detected in 26.7%, and the most common presentation was allergic rhinitis (16.5%). Clinical signs were limited to sun-exposed areas in 75.9% of patients. The light spectrum most commonly implicated was visible light only (31.7%), and in 21% of cases it was only possible to trigger solar urticaria with natural light. The treatments most widely used by photobiology experts were oral antihistamines (65.46%), followed by different forms of phototherapy (34%). Complete resolution was observed most often in patients with solar urticaria triggered exclusively by visible or natural light, with statistically significant differences with respect to other wavelengths (P<.05). No increase in the annual incidence of solar urticaria was observed. CONCLUSIONS: We have presented the largest series of solar urticaria published to date. The epidemiological, clinical, and photobiologic findings confirm previously reported data, although there was a particularly high rate of negative phototests in our series. Reactivity exclusively to visible or natural light was associated with a higher probability of resolution. No increasing trend was observed in the annual incidence.
Assuntos
Transtornos de Fotossensibilidade/etiologia , Luz Solar/efeitos adversos , Urticária/etiologia , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Fenótipo , Transtornos de Fotossensibilidade/epidemiologia , Transtornos de Fotossensibilidade/patologia , Transtornos de Fotossensibilidade/terapia , Fototerapia , Estudos Retrospectivos , Espanha/epidemiologia , Urticária/epidemiologia , Urticária/patologia , Urticária/terapia , Adulto JovemAssuntos
Granuloma Anular/radioterapia , Terapia Ultravioleta/métodos , Corticosteroides/uso terapêutico , Idoso de 80 Anos ou mais , Terapia Combinada , Contraindicações , Feminino , Granuloma Anular/tratamento farmacológico , Humanos , Terapia PUVA , Prednisona/uso terapêutico , Indução de Remissão , Descolamento Retiniano/complicaçõesRESUMO
A portfolio is a collection of material documenting reflection about practice. It contains documents (eg, case histories and questionnaires the resident has used), images, and video recordings that reveal that an individual has acquired the competencies needed for professional practice. This assessment tool simultaneously supports learning and provides evidence for certifying competence. The adoption of portfolio use by a dermatology department requires the support of both the training supervisor and the chief of department. The learning objectives defined by the National Board for Medical-Surgical Dermatology and Venereology must be taken into consideration so that ways to assess each objective can be included; this approach supports holistic ongoing education as well as the certification of competencies the resident finally achieves. Use of portfolios in medical residency training can improve on current assessment methods, which we believe lack precision. We propose that portfolios gradually begin to replace the resident's training log. We are currently developing an online software application that will facilitate the use of portfolios.
Assuntos
Dermatologia/educação , Internato e Residência/métodos , Competência Clínica , Autoavaliação (Psicologia) , Inquéritos e Questionários , Materiais de EnsinoAssuntos
Anticoagulantes/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Fibrinolíticos/uso terapêutico , Heparina de Baixo Peso Molecular/efeitos adversos , Polissacarídeos/uso terapêutico , Idoso de 80 Anos ou mais , Feminino , Fondaparinux , Hirudinas , Humanos , Proteínas Recombinantes/uso terapêuticoRESUMO
OBJECTIVE: To perform a cost-effectiveness analysis, by using a decision tree model, comparing methotrexate with PUVA therapy for moderate to severe chronic plaque psoriasis in the sanitary area of Badajoz (south-western Spain) over a one-year period. MATERIAL AND METHODS: The following variables and data sources were included: efficacy (a 50 % reduction in the PASI) and safety (adverse reactions). Data were retrieved from the dermatologic medical literature, mainly general reviews, systematic reviews and randomized clinical trials. Therapy schedules followed current guidelines from work task teams and consensus documents. Direct costs included unitary costs of medical consults, costs of laboratory tests, pharmacy, phototherapy sessions and costs derived from adverse reactions. Indirect costs included travel expenses and costs of lost productive work time. RESULTS: Unitary cost of methotrexate therapy would be 952.79 euros per treatment (direct cost: 796.48; indirect cost: 156.31). Unitary cost of PUVA therapy would be 899.70 euros per treatment (direct cost: 383.36; indirect cost: 516.34). Total cost of a one-year treatment with methotrexate would be 255,202.73 euros. Total cost of a one-year treatment with PUVA would be 266,406.88 euros. The average cost-effectiveness ratios per case effectively treated would be 1,519.06 euros for methotrexate therapy, and 1,085.18 euros for PUVA therapy. The incremental cost-effectiveness ratio of PUVA/methotrexate would be 150.65 euros for each additional case effectively treated. CONCLUSIONS: One-year treatment for moderate to severe psoriasis in the sanitary area of Badajoz would be more expensive but also more cost-effective with PUVA than with methotrexate. However, indirect costs (borne by patients), are higher for PUVA therapy, a fact that raises an issue of equity. The results should be interpreted taking into account the methodological limitations of a modelling study.